Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2014 Dec 16

PMID 25505295

Citations 63

Authors

Ben A Lopman

Tarak Trivedi

Yosselin Vicuna

Veronica Costantini

Nikail Collins

Nicole Gregoricus

Umesh Parashar

Carlos Sandoval

Nely Broncano

Maritza Vaca

Martha E Chico

Jan Vinje

Philip J Cooper

Affiliations

Soon will be listed here.

Abstract

Background: Although norovirus is the most common cause of gastroenteritis, there are few data on the community incidence of infection/disease or the patterns of acquired immunity or innate resistance to norovirus.

Methods: We followed a community-based birth cohort of 194 children in Ecuador with the aim to estimate (1) the incidence of norovirus gastroenteritis from birth to age 3 years, (2) the protective effect of norovirus infection against subsequent infection/disease, and (3) the association of infection and disease with FUT2 secretor status.

Results: Over the 3-year period, we detected a mean of 2.26 diarrheal episodes per child (range, 0-12 episodes). Norovirus was detected in 260 samples (18%) but was not found more frequently in diarrheal samples (79 of 438 [18%]), compared with diarrhea-free samples (181 of 1016 [18%]; P = .919). A total of 66% of children had at least 1 norovirus infection during the first 3 years of life, and 40% of children had 2 infections. Previous norovirus infections were not associated with the risk of subsequent infection. All genogroup II, genotype 4 (GII.4) infections were among secretor-positive children (P < .001), but higher rates of non-GII.4 infections were found in secretor-negative children (relative risk, 0.56; P = .029).

Conclusions: GII.4 infections were uniquely detected in secretor-positive children, while non-GII.4 infections were more often found in secretor-negative children.

Citing Articles

Norovirus-associated diarrhea and asymptomatic infection in children aged under 4 years: a community-cohort study in the Philippines.

Yu C, Corpuz M, Bonifacio J, Kishi M, Imamura T, Sayama Y IJID Reg. 2025; 14:100549.

PMID: 39877416 PMC: 11773203. DOI: 10.1016/j.ijregi.2024.100549.

Global prevalence of norovirus gastroenteritis after emergence of the GII.4 Sydney 2012 variant: a systematic review and meta-analysis.

Zhang P, Hao C, Di X, Chuizhao X, Jinsong L, Guisen Z Front Public Health. 2024; 12:1373322.

PMID: 38993708 PMC: 11236571. DOI: 10.3389/fpubh.2024.1373322.

A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.

Carlson K, Dilley A, OGrady T, Johnson J, Lopman B, Viscidi E NPJ Vaccines. 2024; 9(1):94.

PMID: 38811605 PMC: 11137017. DOI: 10.1038/s41541-024-00884-2.

Norovirus Disease Among Children <5 Years in 3 Sub-Saharan African Countries: Findings From the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018.

Omore R, Powell H, Sow S, Hossain M, Ogwel B, Doh S Clin Infect Dis. 2023; 76(76 Suppl1):S114-S122.

PMID: 37074441 PMC: 10116553. DOI: 10.1093/cid/ciac967.

Intestinal Norovirus Binding Patterns in Nonsecretor Individuals.

Tarris G, Estienney M, Daval-Frerot P, Lariotte A, Aubignat D, Se K J Virol. 2022; 96(19):e0086522.

PMID: 36121297 PMC: 9555158. DOI: 10.1128/jvi.00865-22.

References

Trujillo A, McCaustland K, Zheng D, Hadley L, Vaughn G, Adams S . Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus. J Clin Microbiol. 2006; 44(4):1405-12. PMC: 1448641. DOI: 10.1128/JCM.44.4.1405-1412.2006. View

Larsson M, Rydell G, Grahn A, Rodriguez-Diaz J, Akerlind B, Hutson A . Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis. 2006; 194(10):1422-7. DOI: 10.1086/508430. View

Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow A . Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol. 2005; 79(11):6714-22. PMC: 1112114. DOI: 10.1128/JVI.79.11.6714-6722.2005. View

Hutson A, Airaud F, Lependu J, Estes M, Atmar R . Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol. 2005; 77(1):116-20. DOI: 10.1002/jmv.20423. View

Marionneau S, Airaud F, Bovin N, Le Pendu J, Ruvoen-Clouet N . Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J Infect Dis. 2005; 192(6):1071-7. DOI: 10.1086/432546. View

Thorven M, Grahn A, Hedlund K, Johansson H, Wahlfrid C, Larson G . A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol. 2005; 79(24):15351-5. PMC: 1315998. DOI: 10.1128/JVI.79.24.15351-15355.2005. View

Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J . A nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS. 2006; 20(5):685-9. DOI: 10.1097/01.aids.0000216368.23325.bc. View

Kindberg E, Akerlind B, Johnsen C, Knudsen J, Heltberg O, Larson G . Host genetic resistance to symptomatic norovirus (GGII.4) infections in Denmark. J Clin Microbiol. 2007; 45(8):2720-2. PMC: 1951234. DOI: 10.1128/JCM.00162-07. View

Tan M, Jin M, Xie H, Duan Z, Jiang X, Fang Z . Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection. J Med Virol. 2008; 80(7):1296-301. DOI: 10.1002/jmv.21200. View

10.

Shirato H, Ogawa S, Ito H, Sato T, Kameyama A, Narimatsu H . Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol. 2008; 82(21):10756-67. PMC: 2573190. DOI: 10.1128/JVI.00802-08. View

11.

Rydell G, Nilsson J, Rodriguez-Diaz J, Ruvoen-Clouet N, Svensson L, Le Pendu J . Human noroviruses recognize sialyl Lewis x neoglycoprotein. Glycobiology. 2008; 19(3):309-20. DOI: 10.1093/glycob/cwn139. View

12.

Carlsson B, Kindberg E, Buesa J, Rydell G, Lidon M, Montava R . The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS One. 2009; 4(5):e5593. PMC: 2680586. DOI: 10.1371/journal.pone.0005593. View

13.

Nordgren J, Kindberg E, Lindgren P, Matussek A, Svensson L . Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis. 2009; 16(1):81-7. PMC: 2874438. DOI: 10.3201/eid1601.090633. View

14.

Phillips G, Tam C, Conti S, Rodrigues L, Brown D, Iturriza-Gomara M . Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol. 2010; 171(9):1014-22. DOI: 10.1093/aje/kwq021. View

15.

de Rougemont A, Ruvoen-Clouet N, Simon B, Estienney M, Elie-Caille C, Aho S . Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol. 2011; 85(9):4057-70. PMC: 3126233. DOI: 10.1128/JVI.02077-10. View

16.

Gladstone B, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman A . Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med. 2011; 365(4):337-46. PMC: 3596855. DOI: 10.1056/NEJMoa1006261. View

17.

Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinje J . Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis. 2011; 17(8):1389-95. PMC: 3381557. DOI: 10.3201/eid1708.101837. View

18.

Atmar R, Bernstein D, Harro C, Al-Ibrahim M, Chen W, Ferreira J . Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011; 365(23):2178-87. PMC: 3761795. DOI: 10.1056/NEJMoa1101245. View

19.

Fischer Walker C, Perin J, Aryee M, Boschi-Pinto C, Black R . Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. BMC Public Health. 2012; 12:220. PMC: 3323412. DOI: 10.1186/1471-2458-12-220. View

20.

Frenck R, Bernstein D, Xia M, Huang P, Zhong W, Parker S . Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis. 2012; 206(9):1386-93. DOI: 10.1093/infdis/jis514. View